$GRST
ETHEMA HEALTH Corp Stock $grst

$grst Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000190359623000646 Filed on August 21, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$1.354M	$1.566M
YoY Change	-4.99%	37.6%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.210M	$1.394M
YoY Change	17.11%	46.45%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$20.69K	$139.6K
YoY Change	-84.85%	3.99%
% of Gross Profit
Operating Expenses	$1.320M	$1.534M
YoY Change	12.86%	41.2%
Operating Profit	$33.53K	$32.15K
YoY Change	-86.85%	-37.9%
Interest Expense	-$148.6K	-$319.3K
YoY Change	-174.91%	53.72%
% of Operating Profit	-443.3%	-993.28%
Other Income/Expense, Net	$110.00	$339.00
YoY Change	-110.53%	-67.56%
Pretax Income	$2.092M	-$451.5K
YoY Change	275.76%	191.45%
Income Tax	-$15.53K	-$219.4K
% Of Pretax Income	-0.74%
Net Earnings	$2.108M	-$232.2K
YoY Change	311.56%	19.8%
Net Earnings / Revenue	155.66%	-14.83%
Basic Earnings Per Share	$0.00	$0.00
Diluted Earnings Per Share	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	3.729B shares	3.729B shares
Diluted Shares Outstanding	3.931B shares	3.729B shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.73K	$27.81K
YoY Change	-97.91%	-59.78%
Cash & Equivalents	$11.73K	$27.81K
Short-Term Investments
Other Short-Term Assets	$62.65K	$55.30K
YoY Change	-7.45%	193.84%
Inventory
Prepaid Expenses	$39.07K	$26.00K
Receivables	$681.1K	$470.8K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$794.5K	$579.9K
YoY Change	-17.25%	22.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$523.7K	$531.3K
YoY Change	-82.32%	-82.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$374.0K	$400.0K
YoY Change	7806.98%	7852.29%
Total Long-Term Assets	$11.21M	$3.256M
YoY Change	94.38%	-46.26%
TOTAL ASSETS
Total Short-Term Assets	$794.5K	$579.9K
Total Long-Term Assets	$11.21M	$3.256M
Total Assets	$12.01M	$3.836M
YoY Change	78.45%	-41.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$129.4K	$131.2K
YoY Change	-63.17%	-65.54%
Accrued Expenses	$32.75K	$311.3K
YoY Change	-88.11%	17.99%
Deferred Revenue
YoY Change
Short-Term Debt	$124.9K	$793.7K
YoY Change	-60.68%	145.32%
Long-Term Debt Due	$23.21K	$23.08K
YoY Change	-99.35%	-99.41%
Total Short-Term Liabilities	$7.713M	$9.857M
YoY Change	-44.99%	-29.71%
LONG-TERM LIABILITIES
Long-Term Debt	$291.7K	$637.2K
YoY Change	-53.74%	-3.25%
Other Long-Term Liabilities	$9.339M	$1.042M
YoY Change	629.55%	-23.01%
Total Long-Term Liabilities	$9.802M	$1.865M
YoY Change	360.75%	-16.99%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.713M	$9.857M
Total Long-Term Liabilities	$9.802M	$1.865M
Total Liabilities	$17.51M	$11.72M
YoY Change	8.46%	-27.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$41.96M	-$44.04M
YoY Change	-4.77%	-1.09%
Common Stock	$37.29M	$37.29M
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.507M	-$7.887M
YoY Change
Total Liabilities & Shareholders Equity	$12.01M	$3.836M
YoY Change	78.45%	-41.29%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	$2.108M	-$232.2K
YoY Change	311.56%	19.8%
Depreciation, Depletion And Amortization	$20.69K	$139.6K
YoY Change	-84.85%	3.99%
Cash From Operating Activities	-$615.8K	-$70.38K
YoY Change	-179.75%	-122.27%
INVESTING ACTIVITIES
Capital Expenditures	$5.224M	-$30.78K
YoY Change	-7419.62%	-78.15%
Acquisitions
YoY Change
Other Investing Activities	$7.719M
YoY Change	-15538.9%
Cash From Investing Activities	$2.495M	$80.78K
YoY Change	-2156.06%	-157.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.890M	-92.52K
YoY Change	-810.59%	-215.06%
NET CHANGE
Cash From Operating Activities	-615.8K	-70.38K
Cash From Investing Activities	2.495M	80.78K
Cash From Financing Activities	-1.890M	-92.52K
Net Change In Cash	-10.03K	-82.12K
YoY Change	-101.09%	-132.13%
FREE CASH FLOW
Cash From Operating Activities	-$615.8K	-$70.38K
Capital Expenditures	$5.224M	-$30.78K
Free Cash Flow	-$5.840M	-$39.60K
YoY Change	-792.29%	-108.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Central Index Key EntityCentralIndexKey	0000792935
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax		usd
CY2022Q2	grst	Penalty On Convertible Debt PenaltyOnConvertibleDebt		usd
	grst	Penalty On Convertible Debt PenaltyOnConvertibleDebt		usd
CY2022Q2	grst	Extension Fee Property Purchase1 ExtensionFeePropertyPurchase1		usd
	grst	Extension Fee Property Purchase1 ExtensionFeePropertyPurchase1		usd
CY2023Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	grst	Penalty On Convertible Promissory Notes PenaltyOnConvertiblePromissoryNotes		usd
	grst	Derivative Liability Movements DerivativeLiabilityMovements		usd
	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable		usd
	grst	Repayment Of Government Assistance Loans RepaymentOfGovernmentAssistanceLoans		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
	grst	Conversion Of Convertible Notes ConversionOfConvertibleNotes		usd
	grst	Fair Value Of Minority Shareholders Interest On Disposal Of Subsidiary FairValueOfMinorityShareholdersInterestOnDisposalOfSubsidiary		usd
	grst	Fair Value Of Minority Shareholders Interest On Disposal Of Subsidiaryone FairValueOfMinorityShareholdersInterestOnDisposalOfSubsidiaryone		usd
CY2023Q2	us-gaap	Principal Amount Outstanding On Loans Securitized PrincipalAmountOutstandingOnLoansSecuritized		usd
	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	dei	Entity File Number EntityFileNumber	000-54748
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Entity Registrant Name EntityRegistrantName	ETHEMA HEALTH CORPORATION.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	CO
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-1227328
	dei	Entity Address Address Line1 EntityAddressAddressLine1	950 Evernia Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	West Palm Beach
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33401
	dei	City Area Code CityAreaCode	(416)
	dei	Local Phone Number LocalPhoneNumber	500-0020
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Security12b Title Security12bTitle	Common shares
	dei	Trading Symbol TradingSymbol	GRST
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3729053805	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27808	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	140757	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	470835	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	337074	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	26000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	44718	usd
CY2023Q2	us-gaap	Other Assets Current OtherAssetsCurrent	55298	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	20347	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	579941	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	542896	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	531298	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2974395	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1073942	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1252932	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1250413	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1393071	usd
CY2023Q2	us-gaap	Deposit Contracts Assets DepositContractsAssets	400000	usd
CY2022Q4	us-gaap	Deposit Contracts Assets DepositContractsAssets	400000	usd
CY2023Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	3255653	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	6020398	usd
CY2023Q2	us-gaap	Assets Assets	3835594	usd
CY2022Q4	us-gaap	Assets Assets	6563294	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	131243	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	170935	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	248644	usd
CY2023Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	5434155	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	5269250	usd
CY2023Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	793660	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	460534	usd
CY2022Q4	us-gaap	Secured Debt SecuredDebt	3504605	usd
CY2023Q2	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	338883	usd
CY2022Q4	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	416731	usd
CY2023Q2	grst	Loans From Other Federal Home Loan Banks Current LoansFromOtherFederalHomeLoanBanksCurrent	14924	usd
CY2022Q4	grst	Loans From Other Federal Home Loan Banks Current LoansFromOtherFederalHomeLoanBanksCurrent	14818	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	311266	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	287017	usd
CY2023Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	8152	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	7891	usd
CY2022Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	194829	usd
CY2023Q2	grst	Related Party Payables RelatedPartyPayables	2824550	usd
CY2022Q4	grst	Related Party Payables RelatedPartyPayables	2713878	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	9856833	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13289131	usd
CY2023Q2	us-gaap	Loans From Other Federal Home Loan Banks LoansFromOtherFederalHomeLoanBanks	27994	usd
CY2022Q4	us-gaap	Loans From Other Federal Home Loan Banks LoansFromOtherFederalHomeLoanBanks	79555	usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	186387	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	217451	usd
CY2023Q2	grst	Third Party Loans ThirdPartyLoans	588372	usd
CY2022Q4	grst	Third Party Loans ThirdPartyLoans	578335	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1041731	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1206413	usd
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	20783	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	24952	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1865267	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2106706	usd
CY2023Q2	us-gaap	Liabilities Liabilities	11722100	usd
CY2022Q4	us-gaap	Liabilities Liabilities	15395837	usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	40000	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	40000	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3729053805	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3729053805	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3729053805	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3729053805	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	37290539	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	37290539	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	25915986	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	23419917	usd
CY2023Q2	us-gaap	Common Stock Discount On Shares CommonStockDiscountOnShares	27363367	usd
CY2022Q4	us-gaap	Common Stock Discount On Shares CommonStockDiscountOnShares	27363367	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5065	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-44036696	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-43484751	usd
CY2023Q2	grst	Stockholders Deficit Attributable To Ethema Health Corporation Stockholders StockholdersDeficitAttributableToEthemaHealthCorporationStockholders	-8153538	usd
CY2022Q4	grst	Stockholders Deficit Attributable To Ethema Health Corporation Stockholders StockholdersDeficitAttributableToEthemaHealthCorporationStockholders	-10102727	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	267032	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	870184	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-7886506	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-9232543	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3835594	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6563294	usd
CY2023Q2	us-gaap	Revenues Revenues	1565959	usd
CY2022Q2	us-gaap	Revenues Revenues	1138032	usd
	us-gaap	Revenues Revenues	2866005	usd
	us-gaap	Revenues Revenues	2161347	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	265165	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	261528	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	506402	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	471460	usd
CY2023Q2	grst	Rent Expense RentExpense	105933	usd
CY2022Q2	grst	Rent Expense RentExpense	109508	usd
	grst	Rent Expense RentExpense	220497	usd
	grst	Rent Expense RentExpense	199539	usd
CY2023Q2	us-gaap	Management Fee Expense ManagementFeeExpense	215503	usd
CY2022Q2	us-gaap	Management Fee Expense ManagementFeeExpense	30000	usd
	us-gaap	Management Fee Expense ManagementFeeExpense	243003	usd
	us-gaap	Management Fee Expense ManagementFeeExpense	60000	usd
CY2023Q2	us-gaap	Professional Fees ProfessionalFees	177910	usd
CY2022Q2	us-gaap	Professional Fees ProfessionalFees	112149	usd
	us-gaap	Professional Fees ProfessionalFees	289114	usd
	us-gaap	Professional Fees ProfessionalFees	161736	usd
CY2023Q2	us-gaap	Salaries And Wages SalariesAndWages	629707	usd
CY2022Q2	us-gaap	Salaries And Wages SalariesAndWages	438842	usd
	us-gaap	Salaries And Wages SalariesAndWages	1221743	usd
	us-gaap	Salaries And Wages SalariesAndWages	875667	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	139595	usd
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	134243	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	278074	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	266243	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	1533813	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	1086270	usd
	us-gaap	Operating Expenses OperatingExpenses	2758833	usd
	us-gaap	Operating Expenses OperatingExpenses	2034645	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	32146	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	51762	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	107172	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	126702	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	339	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1045	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	339	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	11063	usd
CY2023Q2	grst	Penalty On Convertible Debt PenaltyOnConvertibleDebt	-34688	usd
	grst	Penalty On Convertible Debt PenaltyOnConvertibleDebt	-34688	usd
CY2023Q2	grst	Extension Fee Property Purchase1 ExtensionFeePropertyPurchase1	-130000	usd
	grst	Extension Fee Property Purchase1 ExtensionFeePropertyPurchase1	-130000	usd
CY2023Q2	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	143981	usd
CY2022Q2	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	122848	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	301077	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	203616	usd
CY2023Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-87526	usd
CY2022Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-211202	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-164447	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-464034	usd
CY2022Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	67039	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-130437	usd
CY2023Q2	grst	Foreign Exchange Movements ForeignExchangeMovements	-87791	usd
CY2022Q2	grst	Foreign Exchange Movements ForeignExchangeMovements	193368	usd
	grst	Foreign Exchange Movements ForeignExchangeMovements	-90746	usd
	grst	Foreign Exchange Movements ForeignExchangeMovements	97812	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Interest Expense Interest Income Income Taxes Extraordinary Items Noncontrolling Interests Net IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet	-451501	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Interest Expense Interest Income Income Taxes Extraordinary Items Noncontrolling Interests Net IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet	-154914	usd
	us-gaap	Income Loss From Continuing Operations Before Interest Expense Interest Income Income Taxes Extraordinary Items Noncontrolling Interests Net IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet	-613447	usd
	us-gaap	Income Loss From Continuing Operations Before Interest Expense Interest Income Income Taxes Extraordinary Items Noncontrolling Interests Net IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet	-301636	usd
CY2023Q2	grst	Income Taxes IncomeTaxes	219346	usd
CY2022Q2	grst	Income Taxes IncomeTaxes	-24700	usd
	grst	Income Taxes IncomeTaxes	205575	usd
	grst	Income Taxes IncomeTaxes	-42963	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-232155	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-179614	usd
	us-gaap	Net Income Loss NetIncomeLoss	-407872	usd
	us-gaap	Net Income Loss NetIncomeLoss	-344599	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-93880	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-14176	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-96848	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-23638	usd
CY2023Q2	grst	Net Income Loss Allocable To Ethema Health Corporation Stockholders NetIncomeLossAllocableToEthemaHealthCorporationStockholders	-326035	usd
CY2022Q2	grst	Net Income Loss Allocable To Ethema Health Corporation Stockholders NetIncomeLossAllocableToEthemaHealthCorporationStockholders	-193790	usd
	grst	Net Income Loss Allocable To Ethema Health Corporation Stockholders NetIncomeLossAllocableToEthemaHealthCorporationStockholders	-504720	usd
	grst	Net Income Loss Allocable To Ethema Health Corporation Stockholders NetIncomeLossAllocableToEthemaHealthCorporationStockholders	-368237	usd
CY2023Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	5984	usd
CY2022Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	5983	usd
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	11901	usd
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	11901	usd
CY2023Q2	grst	Preferred Stock Dividend Non Controlling Interest PreferredStockDividendNonControllingInterest	-17822	usd
CY2022Q2	grst	Preferred Stock Dividend Non Controlling Interest PreferredStockDividendNonControllingInterest	-18745	usd
	grst	Preferred Stock Dividend Non Controlling Interest PreferredStockDividendNonControllingInterest	-35324	usd
	grst	Preferred Stock Dividend Non Controlling Interest PreferredStockDividendNonControllingInterest	-37440	usd
CY2023Q2	grst	Net Income Loss Available To Common Shareholders Of Ethema Health Corporation NetIncomeLossAvailableToCommonShareholdersOfEthemaHealthCorporation	-349841	usd
CY2022Q2	grst	Net Income Loss Available To Common Shareholders Of Ethema Health Corporation NetIncomeLossAvailableToCommonShareholdersOfEthemaHealthCorporation	-218518	usd
	grst	Net Income Loss Available To Common Shareholders Of Ethema Health Corporation NetIncomeLossAvailableToCommonShareholdersOfEthemaHealthCorporation	-551945	usd
	grst	Net Income Loss Available To Common Shareholders Of Ethema Health Corporation NetIncomeLossAvailableToCommonShareholdersOfEthemaHealthCorporation	-417578	usd
CY2023Q2	us-gaap	Deferred Policy Acquisition Cost Foreign Currency Translation Adjustment And Other DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther	-6569	usd
CY2022Q2	us-gaap	Deferred Policy Acquisition Cost Foreign Currency Translation Adjustment And Other DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther	72869	usd
	us-gaap	Deferred Policy Acquisition Cost Foreign Currency Translation Adjustment And Other DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther	-5065	usd
	us-gaap	Deferred Policy Acquisition Cost Foreign Currency Translation Adjustment And Other DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther	38352	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-343272	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-291387	usd
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-546880	usd
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-455930	usd
CY2023Q2	grst	Income Loss Per Share Basic IncomeLossPerShareBasic	-0.00
CY2022Q2	grst	Income Loss Per Share Basic IncomeLossPerShareBasic	-0.00
	grst	Income Loss Per Share Basic IncomeLossPerShareBasic	-0.00
	grst	Income Loss Per Share Basic IncomeLossPerShareBasic	-0.00
CY2023Q2	grst	Weighted Average Common Shares Outstanding Basic WeightedAverageCommonSharesOutstandingBasic	3729053805	shares
CY2022Q2	grst	Weighted Average Common Shares Outstanding Basic WeightedAverageCommonSharesOutstandingBasic	3729053805	shares
	grst	Weighted Average Common Shares Outstanding Basic WeightedAverageCommonSharesOutstandingBasic	3729053085	shares
	grst	Weighted Average Common Shares Outstanding Basic WeightedAverageCommonSharesOutstandingBasic	3680158777	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-9232543	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	-1504	usd
CY2023Q1	grst	Net Loss NetLoss	-175717	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Dividend Reinvestment Plan StockIssuedDuringPeriodValueDividendReinvestmentPlan	23419	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-9433183	usd
CY2023Q2	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	1334885	usd
CY2023Q2	grst	Gain Loss On Disposition Of Assetsrelated Party GainLossOnDispositionOfAssetsrelatedParty	461184	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	6569	usd
CY2023Q2	grst	Net Loss NetLoss	232155	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Dividend Reinvestment Plan StockIssuedDuringPeriodValueDividendReinvestmentPlan	23806	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-7886506	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-9855381	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	150000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	34517	usd
CY2022Q1	grst	Net Loss NetLoss	-164985	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Dividend Reinvestment Plan StockIssuedDuringPeriodValueDividendReinvestmentPlan	24613	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-9860462	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	-72869	usd
CY2022Q2	grst	Net Loss NetLoss	-179614	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Dividend Reinvestment Plan StockIssuedDuringPeriodValueDividendReinvestmentPlan	24728	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-10137673	usd
	us-gaap	Profit Loss ProfitLoss	-407872	usd
	us-gaap	Profit Loss ProfitLoss	-344599	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	278074	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	266243	usd
	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	164447	usd
	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	464034	usd
	grst	Penalty On Convertible Promissory Notes PenaltyOnConvertiblePromissoryNotes	34688	usd
	grst	Derivative Liability Movements DerivativeLiabilityMovements	-130437	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	142657	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	128195	usd
	grst	Deferred Tax Movement DeferredTaxMovement	31064	usd
	grst	Deferred Tax Movement DeferredTaxMovement	-37588	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	79460	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	169211	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-28034	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-21181	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	339697	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	104282	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-140434	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-117703	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-237211	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	104905	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	35488	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	246940	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	21642	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	213726	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-21642	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-213726	usd
	grst	Repayment Of Mortgage Loans RepaymentOfMortgageLoans	58320	usd
	grst	Repayment Of Mortgage Loans RepaymentOfMortgageLoans	59761	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	10000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	278467	usd
	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	160000	usd
	grst	Repayment Of Government Assistance Loans RepaymentOfGovernmentAssistanceLoans	-7147	usd
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	25970	usd
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	78646	usd
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	3909	usd
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	3661	usd
	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	265750	usd
	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	195500	usd
	us-gaap	Repayments Of Accounts Receivable Securitization RepaymentsOfAccountsReceivableSecuritization	448905	usd
	us-gaap	Repayments Of Accounts Receivable Securitization RepaymentsOfAccountsReceivableSecuritization	15000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	78246	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	207294	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-210255	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	127259	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83460	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-140150	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-112949	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	20323	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	140757	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48822	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27808	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69145	usd
	us-gaap	Interest Paid Net InterestPaidNet	90888	usd
	us-gaap	Interest Paid Net InterestPaidNet	86733	usd
	grst	Conversion Of Convertible Notes ConversionOfConvertibleNotes	150000	usd
	grst	Fair Value Of Minority Shareholders Interest On Disposal Of Subsidiary FairValueOfMinorityShareholdersInterestOnDisposalOfSubsidiary	1334885	usd
	grst	Fair Value Of Minority Shareholders Interest On Disposal Of Subsidiaryone FairValueOfMinorityShareholdersInterestOnDisposalOfSubsidiaryone	461184	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_804_eus-gaap--NatureOfOperations_zfajtEEOVTn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>1. <span id="xdx_826_zSXOmmC6JxE7">Nature of business</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Since 2010, the Company has operated addiction treatment centers. Initially the Company operated an addiction treatment center in Ontario Canada under its Greenestone Muskoka clinic, which was sold on February 14, 2017. Simultaneously with this sale the Company purchased buildings and operated an addiction treatment center in Delray Beach, Florida under its Addiction Recovery Institute of America subsidiary with a license obtained in December 2016, initially through owned properties in Delray Beach and subsequently though leased properties in West Palm Beach, Florida. Since June 30, 2020, the Company has been actively involved in the management of a treatment center operated by Evernia in West Palm Beach, Florida. On July 1, 2021, the Company closed on the acquisition of 75% of ATHI, which owns 100% of Evernia, once the probationary approval of a license was obtained from the Department of Children and Family Services of Florida. Evernia is the only active treatment center operated by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">The Company also owned the real estate on which its Greenstone Muskoka clinic operated. The current tenant operates an addiction treatment center on these premises. The Company collected rent on this property, which is treated as a separate business segment.<b> </b>Om June 30, 2023, the Company sold Cranberry Cove Holdings, in which the real estate was registered to Leonite Capital, in exchange for the cancellation of preferred shares and the accrued dividend liability owed on the preferred shares. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> <b> </b></span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_zeBKSbVfzvz2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>a) <span id="xdx_86E_zs0XLNH1V839">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	656189	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	124891	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	531298	usd
CY2022Q4	grst	Property Plant And Equipment Net1 PropertyPlantAndEquipmentNet1	2974395	usd
CY2023Q2	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet	12015	usd
CY2023Q2	us-gaap	Disposal Group Including Discontinued Operation Property Plant And Equipment Current DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent	2420499	usd
CY2023Q2	us-gaap	Disposal Group Including Discontinued Operation Accounts Payable And Accrued Liabilities Current DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent	196859	usd
CY2023Q2	grst	Disposal Group Including Discontinued Operation Government Assistance Loans DisposalGroupIncludingDiscontinuedOperationGovernmentAssistanceLoans	-45317	usd
CY2023Q2	us-gaap	Disposal Group Including Discontinued Operation Other Noncurrent Liabilities DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities	3525223	usd
	grst	Finite Lived Intangible Asset Useful Life One FiniteLivedIntangibleAssetUsefulLifeOne	5 years
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1789903	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	715961	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1073942	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1252932	usd
CY2023Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	32484	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	38079	usd
CY2023Q2	grst	Rightofuse Assets Operating Leases Net Of Amortization RightofuseAssetsOperatingLeasesNetOfAmortization	1250413	usd
CY2022Q4	grst	Rightofuse Assets Operating Leases Net Of Amortization RightofuseAssetsOperatingLeasesNetOfAmortization	1393071	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	5595	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	5595	usd
	grst	Interest Expense On Finance Lease Liabilitie InterestExpenseOnFinanceLeaseLiabilitie	1031	usd
	grst	Interest Expense On Finance Lease Liabilitie InterestExpenseOnFinanceLeaseLiabilitie	1279	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	6626	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	6874	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	173644	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	199539	usd
	us-gaap	Lease Cost LeaseCost	181301	usd
	us-gaap	Lease Cost LeaseCost	206413	usd
	grst	Operating Cash Flows From Finance Leases OperatingCashFlowsFromFinanceLeases	-1031	usd
	grst	Operating Cash Flows From Finance Leases OperatingCashFlowsFromFinanceLeases	-1279	usd
	grst	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	-173644	usd
	grst	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	-199539	usd
	grst	Financing Cash Flows From Finance Leases FinancingCashFlowsFromFinanceLeases	-3883	usd
	grst	Financing Cash Flows From Finance Leases FinancingCashFlowsFromFinanceLeases	-3661	usd
	grst	Net Change In Leases NetChangeInLeases	-178558	usd
	grst	Net Change In Leases NetChangeInLeases	-204479	usd
	grst	Discount Rate Finance Leases DiscountRateFinanceLeases	0.0661	pure
	grst	Discount Rate Finance Leases DiscountRateFinanceLeases	0.0661	pure
	grst	Discount Rate Operating Leases DiscountRateOperatingLeases	0.0464	pure
	grst	Discount Rate Operating Leases DiscountRateOperatingLeases	0.0464	pure
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	9829	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	9829	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	6195	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	1707	usd
CY2023Q2	grst	Total Undiscounted Minimum Future Lease Payment TotalUndiscountedMinimumFutureLeasePayment	32475	usd
CY2023Q2	grst	Imputed Interest ImputedInterest	-3540	usd
CY2023Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	28935	usd
CY2023Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	8152	usd
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	20783	usd
CY2023Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	28935	usd
CY2023Q2	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	175033	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	366110	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	384416	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	403637	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	33771	usd
CY2023Q2	grst	Total Undiscounted Minimum Future Lease Payments TotalUndiscountedMinimumFutureLeasePayments	1362967	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9970	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1352997	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	311266	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1041731	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1352997	usd
	grst	Debt Instrument Of Principal Amount DebtInstrumentOfPrincipalAmount	4413442	usd
	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	1020713	usd
	grst	Shortterm Convertible ShorttermConvertible	5434155	usd
CY2022	grst	Shortterm Convertible ShorttermConvertible	5269250	usd
CY2023Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.042	pure
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	623777506	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.0052875
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	20925000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.12
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	602852506	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.001306
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	602852506	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.001306
	grst	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceTerm	P2Y14D
	grst	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceTerm1	P2Y6M7D
CY2023Q1	grst	Warrants Outstanding WarrantsOutstanding	602852506	shares
	grst	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price Term2 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceTerm2	P2Y3M3D
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001306
	grst	Warrants Exercisable WarrantsExercisable	602852506	shares
CY2023Q1	grst	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercisable ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable	0.001306
CY2023Q2	grst	Net Income Per Share Available For Common Stockholders NetIncomePerShareAvailableForCommonStockholders	-232155	usd
CY2023Q2	grst	Numbers Of Shares Net Income Per Share Available For Common Stockholders NumbersOfSharesNetIncomePerShareAvailableForCommonStockholders	3729053805	shares
CY2023Q2	grst	Per Share Amount PerShareAmount	-0.00
	grst	Net Income Per Share Available For Common Stockholders NetIncomePerShareAvailableForCommonStockholders	-407872	usd
	grst	Numbers Of Shares Net Income Per Share Available For Common Stockholders NumbersOfSharesNetIncomePerShareAvailableForCommonStockholders	3729053805	shares
	grst	Per Share Amount PerShareAmount	-0.00
CY2022Q2	grst	Net Income Per Share Available For Common Stockholders NetIncomePerShareAvailableForCommonStockholders	-218518	usd
CY2022Q2	grst	Numbers Of Shares Net Income Per Share Available For Common Stockholders NumbersOfSharesNetIncomePerShareAvailableForCommonStockholders	3729053805	shares
CY2022Q2	grst	Per Share Amount PerShareAmount	-0.00
	grst	Net Income Per Share Available For Common Stockholders NetIncomePerShareAvailableForCommonStockholders	-417578	usd
	grst	Numbers Of Shares Net Income Per Share Available For Common Stockholders NumbersOfSharesNetIncomePerShareAvailableForCommonStockholders	3729053805	shares
	grst	Per Share Amount PerShareAmount	-0.00
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1275143076	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	929744111	shares

Files In Submission

Name	View Source	Status
grst-20230630_def.xml	Edgar Link	unprocessable
0001903596-23-000646-index-headers.html	Edgar Link	pending
0001903596-23-000646-index.html	Edgar Link	pending
0001903596-23-000646.txt	Edgar Link	pending
0001903596-23-000646-xbrl.zip	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
grst-20230630.xsd	Edgar Link	pending
grst_10q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
grst-20230630_cal.xml	Edgar Link	unprocessable
grst-20230630_pre.xml	Edgar Link	unprocessable
grst-20230630_lab.xml	Edgar Link	unprocessable
grst_10q_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GRST
ETHEMA HEALTH Corp Stock $grst

2023 Q3 Form 10-Q Financial Statement

#000190359623000646 Filed on August 21, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GRST ETHEMA HEALTH Corp Stock $grst

2023 Q3 Form 10-Q Financial Statement

#000190359623000646 Filed on August 21, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GRST
ETHEMA HEALTH Corp Stock $grst